Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.

Enudi, W; Udolu, O J

dc.contributor.author	Enudi, W
dc.contributor.author	Udolu, O J
dc.date.accessioned	2010-03-10T10:07:42Z
dc.date.available	2010-03-10T10:07:42Z
dc.date.issued	2009-08
dc.identifier.citation	Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma. 2009, 12 (3):227-8 Afr J Psychiatry (Johannesbg)	en
dc.identifier.issn	1994-8220
dc.identifier.pmid	19750253
dc.identifier.uri	http://hdl.handle.net/10147/94035
dc.description.abstract	Several adverse effects have been associated with interferon alpha 2b treatment and neuropsychiatric effects have also been commonly reported. Psychosis and mood disorders have been described in the literature. This case report is of a 30 year old man with malignant melanoma stage 3a who was receiving adjuvant alpha 2b interferon and developed a manic episode two weeks post switching after one month of treatment on a high dose to a low dose. There was no previous psychiatric illness and no known family history of mental illness. This is in keeping with previous reports that mania has been observed in patients undergoing interferon treatment especially after significant dose-reduction or treatment breaks. Mania induced by interferon responds well to antimanic drugs .Since interferon alpha 2b is now commonly used in the treatment of malignant melanoma and other conditions, the need to be aware of its neuropsychiatric complications is essential.
dc.language.iso	en	en
dc.subject.mesh	Adult
dc.subject.mesh	Antimanic Agents
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Antipsychotic Agents
dc.subject.mesh	Benzodiazepines
dc.subject.mesh	Bipolar Disorder
dc.subject.mesh	Dose-Response Relationship, Drug
dc.subject.mesh	Humans
dc.subject.mesh	Interferon Alfa-2b
dc.subject.mesh	Male
dc.subject.mesh	Melanoma
dc.subject.mesh	Skin Neoplasms
dc.title	Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.	en
dc.contributor.department	Adelaide and Meath Hospital, Tallaght, Ireland. waltenudi@yahoo.com	en
dc.identifier.journal	African journal of psychiatry	en
refterms.dateFOA	2018-09-03T10:28:57Z
html.description.abstract	Several adverse effects have been associated with interferon alpha 2b treatment and neuropsychiatric effects have also been commonly reported. Psychosis and mood disorders have been described in the literature. This case report is of a 30 year old man with malignant melanoma stage 3a who was receiving adjuvant alpha 2b interferon and developed a manic episode two weeks post switching after one month of treatment on a high dose to a low dose. There was no previous psychiatric illness and no known family history of mental illness. This is in keeping with previous reports that mania has been observed in patients undergoing interferon treatment especially after significant dose-reduction or treatment breaks. Mania induced by interferon responds well to antimanic drugs .Since interferon alpha 2b is now commonly used in the treatment of malignant melanoma and other conditions, the need to be aware of its neuropsychiatric complications is essential.